Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2025 · View financials
Decision snapshot: SRPT stock price vs DUK: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at DUK's multiple
Needs DUK P/S.
Implied fair value · at SRPT's multiple
Needs SRPT P/S.
Metric by metric
Live quote
Price unavailable
Where each company leads, and how wide the gap is.
Growth edge
Pricing power
Operating leverage
Lower is better
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: SRPT FY 2025 (ended Dec 31, 2025) · DUK FY 2025 (ended Dec 31, 2025).
Trendline
Five fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Price framework
Discounted free cash flow, then bridged to a per-share price. Same assumptions applied to both companies.
SAREPTA THERAPEUTICS, INC. · implied price per share
Bear
-$43.23
Base
-$50.86
Bull
-$58.48
Duke Energy CORP · implied price per share
Bear
$30.13
Base
$35.45
Bull
$40.76
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Debt / equity
Total debt against shareholders' equity
0.82x
1.73x
Net debt / EBITDA
Leverage against operating earnings
0.01x
6.40x
Cash and equivalents
Liquid reserves on the balance sheet
$939.65M
$7.70B
Total debt
Interest-bearing obligations outstanding
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
AMGEN INC
SRPT vs AMGN
BIOMARIN PHARMACEUTICAL INC
SRPT vs BMRN
Replimune Group, Inc.
SRPT vs REPL
PTC THERAPEUTICS, INC.
SRPT vs PTCT
NEXTERA ENERGY INC
SRPT vs NEE
SOUTHERN CO
SRPT vs SO
DOMINION ENERGY, INC
SRPT vs D
EXELON CORP
SRPT vs EXC
American Electric Power Company, Inc.
SRPT vs AEP
XCEL ENERGY INC
SRPT vs XEL
$934.46M
$89.84B
Live quote
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
Based on an earlier data snapshot. Review the filing dates below or refresh after signing in.
If you believe SRPT can convert its 15.6% revenue growth into sustained positive margins and improve its quality scores, then the stock looks attractive versus the 0.9x P/S DUK comparison; otherwise, the current price near the top of its historical band argues for caution because the valuation gap is not yet supported by profitability.
SRPT trades at 0.9x P/S versus DUK at 3.2x P/S, which implies a large theoretical upside to $66.65 from the current $19.28 price. However, DUK-based valuation is stretched by very different business models and is not supported by SRPT’s current earnings and margin profile.
Supporting Metrics
